RDS2 Solutions
RDS 2 Solutions is dedicated to developing promising novel medicines to help and potentially cure patients suffering from Idiopathic Pulmonary Fibrosis, a disease with over 5 million cases worldwide annually. They focus on using Vasoactive Intestinal Peptide (VIP) to treat lung diseases, including pulmonary fibrosis, with the aim of providing improved efficacy and lower side effects compared to current FDA-approved drugs. The company is led by a team of experienced professionals including President & CEO Anthony Szema, MD, and other senior executives. They are involved in innovative research, clinical trials, and have a strong commitment to saving lives through medical advancements.
Industries
Nr. of Employees
small (1-50)
RDS2 Solutions
Long Island High Technology Incubator, 25 Health Sciences Drive, Suite 208-B, Stony Brook, NY 11794
Products
VIP-based therapeutic candidate for idiopathic pulmonary fibrosis
A peptide-based therapeutic candidate derived from Vasoactive Intestinal Peptide intended to reduce inflammation and promote healing in pulmonary fibrosis and related lung injuries; in preclinical/translational development with plans for early-phase clinical trials.
VIP-based therapeutic candidate for idiopathic pulmonary fibrosis
A peptide-based therapeutic candidate derived from Vasoactive Intestinal Peptide intended to reduce inflammation and promote healing in pulmonary fibrosis and related lung injuries; in preclinical/translational development with plans for early-phase clinical trials.
Services
Design and operational planning for early-phase clinical trials (safety and proof-of-concept) for novel therapeutics.
Conduct of animal-model experiments and translational studies to evaluate therapeutic candidate efficacy and mechanism of action.
Large-scale data management, statistical analysis, and process-improvement initiatives to optimize clinical operations and research outcomes.
Preparation of grant proposals, budget and indirect cost planning, and administration of awarded federal grants.
Valuation analysis, due diligence support, and market-entry strategy for in-licensing and commercialization of early-stage therapeutics.
Design and operational planning for early-phase clinical trials (safety and proof-of-concept) for novel therapeutics.
Conduct of animal-model experiments and translational studies to evaluate therapeutic candidate efficacy and mechanism of action.
Large-scale data management, statistical analysis, and process-improvement initiatives to optimize clinical operations and research outcomes.
Preparation of grant proposals, budget and indirect cost planning, and administration of awarded federal grants.
Valuation analysis, due diligence support, and market-entry strategy for in-licensing and commercialization of early-stage therapeutics.
Expertise Areas
- Therapeutic peptide development
- Idiopathic pulmonary fibrosis and pulmonary disease research
- Clinical trial management (early-phase)
- Translational research and academic partnerships
Key Technologies
- Therapeutic peptide development (VIP-based)
- Preclinical animal disease models
- Exosome isolation
- Primary muscle fiber culture